key: cord-0686384-dladwhgp
authors: Costanzo, Luca; Palumbo, Francesco Paolo; Ardita, Giorgio; Antignani, Pier Luigi; Arosio, Enrico; Failla, Giacomo
title: Coagulopathy, thromboembolic complications and the use of heparin in COVID-19 Pneumonia
date: 2020-06-17
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2020.05.018
sha: 80f100a257aedbee382e3449bcda1e3d7285659e
doc_id: 686384
cord_uid: dladwhgp

The SARS-CoV-2 (COVID-19) is causing a pandemic and potentially fatal disease, actually of global public health concern. Viral infections are known to be associated with coagulation impairment thus thrombosis, hemorrhage, or both, may occur. Understanding the pathophysiological mechanisms underlying the development of coagulation disorders during viral infection is essential for the development of therapeutic strategies. Coagulopathy in COVID-19 infection is emerging as a precipitant factor for severe respiratory complications and death. An increase in coagulation markers such as fibrinogen and D-Dimer has been found in severe COVID-19 cases. Heparin, clinically used as an anticoagulant, has also anti-inflammatory properties including binding of inflammatory cytokines, inhibition of neutrophil chemotaxis, protection of endothelial cells and a potential antiviral effect. We hypothesized that low molecular weight heparin (LMWH) may attenuate cytokine storm in COVID-19 patients therefore LMWH could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy. In this paper we review potential mechanisms involved in coagulation impairment following viral infection and the possible role of heparin in the treatment of COVID-19 patients.

NETs) are produced to allow neutrophils to trap and kill external microorganisms. NETs 1 stimulate the formation and deposition of fibrin in order to trap microorganisms and control 2 infection [11] . NETs also cause platelet adhesion and a link with deep vein thrombosis 3 occurrence has been shown in some experimental models [12] . 4 D-dimer is an epitope resulting from the plasmin degradation of cross-linked fibrin. D-dimer 5 elevates in several conditions such as thrombosis, DIC and inflammation [13] . Notably, D-Dimer 6

can promote the development of inflammation by activating neutrophils and monocytes, 7

inducing the secretion of some inflammatory cytokines [14, 15] . 8 9

In several viral infections, the impairment of platelet function, decrease in production or platelet 11 destruction has been documented. Thrombocytopenia can occur in both hemorrhagic and non-12 hemorrhagic viral infections and it is frequently caused by autoimmune antibodies against 13 platelets. Other mechanisms include increased platelet adhesion and activation resulting in 14 platelet consumption and bone marrow infection that directly affects megakaryocytes and thus 15 platelet production [5] . In SARS-CoV infection, thrombocytopenia caused by autoantibodies, the 16 presence of high levels of von Willebrand factor in the blood [16] and activation of the 17 coagulation cascade with final generation of fibrin have been described [17] [18] [19] [20] . 18

In COVID-19 disease, thrombocytopenia at hospital admission does not seem to be a consistent 19

factor, as in a study of 41 patients it was found in only 2 patients [21] . However, in a recent 20 meta-analysis of nine studies including nearly 400 patients, the platelet count was significantly 21 lower in patients with more severe COVID-19; also, thrombocytopenia was associated with over 22 fivefold increased risk of severe COVID-19 disease [22] . 23 1

A procoagulative state can be evidenced through an increase in the levels of coagulation 3

proteins. Increased levels of fibrinogen, D-dimer, thrombin-antithrombin complexes and / or 4 plasmin-alpha-2-antiplasmin complexes and thrombomodulin have been found in respiratory 5 tract infections, influenza and SARS-CoV infection. Furthermore, an increased level of the 6 plasminogen-1 activator inhibitor, suggestive of impaired fibrinolysis, was also reported [5] . 7

Recently, alterations in laboratory parameters compatible with DIC criteria have been described 8 by Tang and collaborators in 15 deaths for COVID-19 [4] . DIC develops as a result of 9 monocytes and endothelial cells activation due to cytokine release following injury, with 10 expression of tissue factor and secretion of von Willebrand factor. Final result is the circulation 11 of free thrombin that can activate platelets and stimulate fibrinolysis with elevated levels of D-12 dimer and fibrinogen degradation products. Therefore, in the final stage of disease, high levels of 13 D-dimer and products of the degradation of fibrinogen have been reported; also markedly 14 elevated D-dimers correlated with more severe disease and mortality [4, 23, 24] . Surface plasmon resonance and circular dichroism, two spectroscopic techniques for molecular 9 analysis, have been used in a recent work and showed that the binding domain of the Spike S1 10 SARS-CoV-2 protein receptor interacts with the heparin [54] . 11

Potential mechanisms of LMWH action in COVID-19 disease are described in figure 2 . 12

Finally, in the recent report by Tang and collaborators, a favorable outcome was highlighted with 13 the use of LMWH in severe COVID-19 patients meeting sepsis-induced coagulopathy (SIC) 14 criteria ( Table 1) The reported data suggested that in many cases the infection may have an asymptomatic course 3

[56]. The use of heparin is probably unnecessary in this population. However, in case of the 4 onset and persistence of respiratory symptoms, even in patients in isolation at home, it is 5 considered useful to start a prophylaxis with LMWH or with Fondaparinux if renal function is 6 preserved (creatinine clearance > 50 ml/min). Should the patient develop a progressive 7 worsening of respiratory symptoms in association with the increase in coagulation markers, 8 therapeutic / sub-therapeutic doses of LMWH could be hypothesized, taking into account the 9 clinical characteristics and hemorrhagic risk, however a definitive recommendation cannot be 10 provided because of the lack of consistent published data. In advanced states, as powerful 11 intravascular generation of thrombin occurs, unfractionated heparin could have a role, especially 12 in cases of severe renal failure (creatinine clearance < 30 ml/min) because of impaired LMWH 13 renal excretion. Furthermore, in these patients, careful monitoring of the coagulation parameters 14 is necessary due to the possible development of DIC in the end stage of the disease [4] . Coagulation Platelet count (×10 9 /L) ≧150 <150 <100

Total SOFA SOFA four items * 0 1 ≧2

*Total SOFA is the sum the four items (respiratory SOFA, cardiovascular SOFA, hepatic SOFA, renal SOFA). The SOFA score was included to confirm the presence of sepsis but does not reflect the sepsis severity; therefore, the score for SOFA was limited to two points even if the SOFA score was more than two (adapted from reference n° 55).

INR, international normalisation ratio; PT, prothrombin time; SOFA, Sequential Organ Failure Assessment.

Acute pulmonary embolism and COVID-19 2 pneumonia: a random association?

COVID-19 Complicated by Acute Pulmonary

Abnormal coagulation parameters are associated with 6 poor prognosis in patients with novel coronavirus pneumonia

Viral 9 infections and mechanisms of thrombosis and bleeding

The Role of Inflammation in Venous Thromboembolism

Linking endothelial dysfunction with endothelial cell activation

Platelet Activation: The Mechanisms and 15

Leukocyte-endothelial interactions in inflammation

Inflammation, innate immunity and blood coagulation

Innate immunity and coagulation

Neutrophil extracellular trap (NET) impact on deep vein 23 thrombosis

Evidence for the important role 2 of inflammation in xenotransplantation

Fibrin degradation product D-dimer induces the 4 synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors 5 from monocytes in vitro

D-dimer correlates with 7 proinflammatory cytokine levels and outcomes in critically ill patients

Analysis of thrombotic factors 9 in severe acute respiratory syndrome (SARS) patients

Haematological 11 manifestations in patients with severe acute respiratory syndrome: Retrospective analysis

A major outbreak of severe 14 acute respiratory syndrome in Hong Kong

Analysis of deaths during 16 the severe acute respiratory syndrome (SARS) epidemic in Singapore: Challenges in determining 17 a SARS diagnosis

Pulmonary 19 pathology of severe acute respiratory syndrome in Toronto

COVID-19) infections: A meta-analysis

Clinical characteristics of 3 coronavirus disease 2019 in China

Clinical course and risk factors for 5 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Disseminated intravascular coagulation

Risk of deep vein 9 thrombosis and pulmonary embolism after acute infection in a community setting

Hemostatic disorders in bird flu infection

Elevated Plasmin(ogen) as a Common Risk 14 Factor for COVID-19 Susceptibility

Circulating, interferon-producing plasmacytoid dendritic cells 16 decline during human ageing

Exacerbated innate host response to 18 SARS-CoV in aged non-human primates

Effects of aging on the adaptive immune response to respiratory 20 virus infections

Molecular pathology of emerging coronavirus infections

COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi

Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. 2020. In press

Complement 7 associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 8 infection: a report of five cases

Anticoagulants: A Review of the 10

The Inhibition of Blood Clotting: An 12

Unidentified Substance Which Acts in Conjunction with Heparin to Prevent the Conversion of 13

Antithrombin-Binding Site in Heparin

Heparin Oligosaccharides and Their Neutralization by Platelet Factor 4

Multiple Functional Domains of the 20

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing

The versatile heparin in COVID-19

Extracellular 14 histones are major mediators of death in sepsis

Heparins attenuated histone-16 mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ 17 dysfunction

Unfractionated heparin attenuates histone-19 mediated cytotoxicity in vitro and prevents intestinal microcirculatory dysfunction in histone-20 infused rats

Protective effects of heparin on endothelial cells in sepsis

Herpesviruses and heparan sulfate: an intimate relationship in aid of 1 viral entry

Heparin 3 prevents Zika virus induced-cytopathic effects in human neural progenitor cells

Coronaviridae 6 and SARS-associated coronavirus strain HSR1

Anticoagulant treatment is associated with 9 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Empirical 12 systemic anticoagulation is associated with decreased venous thromboembolism in critically ill 13 influenza A H1N1 acute respiratory distress syndrome patients

Covid-19: four fifths of cases are asymptomatic, China figures indicate